{"title":"复发性喉乳头状瘤病的晚期治疗","authors":"S. Murono, T. Yoshizaki","doi":"10.5426/LARYNX.26.77","DOIUrl":null,"url":null,"abstract":"Cidofovir is an anti-viral agent and has been anticipated to eradicate human papillomavirus in cases of recurrent respiratory papillomatosis (RRP). We herein summarize four new cases of more severe RRP than have been previously reported, which were treated with intralesional injection of the agent. Three of the four cases achieved minimal residual disease. However, recurrence of the disease was observed in all three cases, and further surgical intervention with intralesional injection of the agent was attempted. The remaining case had very severe disease requiring reduction of the tumor volume at the initial injection. Repeated recurrence required further surgical interventions with intralesional injection of the agent. The trends in Europe and the United States of America, as seen in statements approved by the RRP Task Force, should be considered when performing the treatment.","PeriodicalId":126820,"journal":{"name":"THE LARYNX JAPAN","volume":"71 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advanced Treatment for Recurrent Laryngeal Papillomatosis\",\"authors\":\"S. Murono, T. Yoshizaki\",\"doi\":\"10.5426/LARYNX.26.77\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cidofovir is an anti-viral agent and has been anticipated to eradicate human papillomavirus in cases of recurrent respiratory papillomatosis (RRP). We herein summarize four new cases of more severe RRP than have been previously reported, which were treated with intralesional injection of the agent. Three of the four cases achieved minimal residual disease. However, recurrence of the disease was observed in all three cases, and further surgical intervention with intralesional injection of the agent was attempted. The remaining case had very severe disease requiring reduction of the tumor volume at the initial injection. Repeated recurrence required further surgical interventions with intralesional injection of the agent. The trends in Europe and the United States of America, as seen in statements approved by the RRP Task Force, should be considered when performing the treatment.\",\"PeriodicalId\":126820,\"journal\":{\"name\":\"THE LARYNX JAPAN\",\"volume\":\"71 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"THE LARYNX JAPAN\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5426/LARYNX.26.77\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"THE LARYNX JAPAN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5426/LARYNX.26.77","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Advanced Treatment for Recurrent Laryngeal Papillomatosis
Cidofovir is an anti-viral agent and has been anticipated to eradicate human papillomavirus in cases of recurrent respiratory papillomatosis (RRP). We herein summarize four new cases of more severe RRP than have been previously reported, which were treated with intralesional injection of the agent. Three of the four cases achieved minimal residual disease. However, recurrence of the disease was observed in all three cases, and further surgical intervention with intralesional injection of the agent was attempted. The remaining case had very severe disease requiring reduction of the tumor volume at the initial injection. Repeated recurrence required further surgical interventions with intralesional injection of the agent. The trends in Europe and the United States of America, as seen in statements approved by the RRP Task Force, should be considered when performing the treatment.